Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2021-10-04 00:00:00 ET · period of report 2021-09-30 · accession 0001591986-21-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2021-10-04 | 2021-09-30 | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $18.65 | +134.5K | 4.56M | +3% | +$2.51M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value | 2021-09-30 | P | A | 134,543 | $18.65 | 4,563,688 | I See Footnotes | — | — | (F1) The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of, Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein. (F2) Aquilo Capital, LP owns only 3,378,881 of the 4,563,688 shares deemed to be beneficially owned by Aquilo Capital Management, LLC. Aquilo Capital, LP did not purchase any of the 134,543 shares purchased in this transaction on 09/30/2021. |